Surface Oncology, Inc. (SURF): Price and Financial Metrics

Surface Oncology, Inc. (SURF): $1.07

0.01 (-0.93%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

B

Add SURF to Watchlist
Sign Up

SURF Price/Volume Stats

Current price $1.07 52-week high $1.43
Prev. close $1.08 52-week low $0.56
Day low $1.01 Volume 1,510,100
Day high $1.09 Avg. volume 430,375
50-day MA $0.96 Dividend yield N/A
200-day MA $0.82 Market Cap 65.08M

SURF Stock Price Chart Interactive Chart >


Surface Oncology, Inc. (SURF) Company Bio


Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company’s lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.


SURF Latest News Stream


Event/Time News Detail
Loading, please wait...

SURF Latest Social Stream


Loading social stream, please wait...

View Full SURF Social Stream

Latest SURF News From Around the Web

Below are the latest news stories about SURFACE ONCOLOGY INC that investors may wish to consider to help them evaluate SURF as an investment opportunity.

Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M

Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surface acquisition adds two clinical stage assets to Coherus' I-O pipeline: SRF388, currently in Phase 2 trials in lung and liver cancer, and SFR114, currently in a Phase 1/2 study as a monotherapy for advanced solid tumors. Coherus will issue shares at $5.2831 per s

Yahoo | June 16, 2023

Coherus to Acquire Surface Oncology

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus’ I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs– – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 million at closing; Surface shareholders will also

Yahoo | June 16, 2023

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023

Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding into the third quarter of 2024 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fir

Yahoo | May 4, 2023

Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023

– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models –CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research (

Yahoo | April 18, 2023

Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present a poster highlighting new preclinical data for SRF114, the company’s fully human, afucosylated anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, 2023, in Orlando, Fl. Details on the p

Yahoo | March 16, 2023

Read More 'SURF' Stories Here

SURF Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 57.33%
3-year -84.24%
5-year -73.65%
YTD N/A
2023 0.00%
2022 -82.85%
2021 -48.27%
2020 391.49%
2019 -55.66%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!